Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BV GA733-2E is a recombinant protein cancer vaccine consisting of the extracellular domain of the GA733-2 antigen, which is also known as EpCAM (Epithelial Cell Adhesion Molecule), CO17-1A, or KSA. The protein is expressed using a baculovirus (BV) vector system. It was developed as an active immunotherapy for colorectal carcinoma (CRC) to induce both humoral (antibody) and cellular (T-cell) immune responses against tumor cells expressing the GA733-2 antigen. Unlike anti-idiotypic antibodies that mimic a single epitope, BV GA733-2E contains multiple potentially immunogenic epitopes of the extracellular domain. In clinical trials, it has been administered with aluminum hydroxide as an adjuvant.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BV GA733-2E.